MediWound (NASDAQ:MDWD) Cut to “Hold” at Zacks Research

MediWound (NASDAQ:MDWD) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

MDWD has been the subject of a number of other reports. Alliance Global Partners initiated coverage on MediWound in a report on Friday, May 2nd. They set a “buy” rating and a $25.00 price objective for the company. HC Wainwright set a $31.00 price target on MediWound and gave the company a “buy” rating in a research note on Thursday, May 22nd. Oppenheimer began coverage on MediWound in a research note on Monday, June 2nd. They issued an “outperform” rating and a $34.00 price target for the company. Finally, Wall Street Zen downgraded MediWound from a “hold” rating to a “sell” rating in a research note on Friday, July 18th. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, MediWound presently has an average rating of “Moderate Buy” and an average price target of $32.25.

MediWound Price Performance

NASDAQ MDWD opened at $17.44 on Tuesday. The firm has a market cap of $188.49 million, a P/E ratio of -6.61 and a beta of 0.21. The stock’s 50-day moving average is $19.40 and its 200-day moving average is $18.58. MediWound has a one year low of $14.14 and a one year high of $22.50.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.68). The business had revenue of $5.71 million for the quarter, compared to analyst estimates of $5.68 million. MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%. Equities analysts anticipate that MediWound will post -2.66 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers boosted its stake in shares of MediWound by 4.4% during the 1st quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 481 shares during the period. Russell Investments Group Ltd. lifted its holdings in MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares during the last quarter. Corebridge Financial Inc. lifted its holdings in MediWound by 17.1% during the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 665 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the last quarter. Finally, Barclays PLC lifted its holdings in MediWound by 11.2% during the 4th quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company’s stock worth $221,000 after purchasing an additional 1,249 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.